Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors and classification in multiple myeloma.

J F San Miguel1, J Sànchez, M Gonzalez

  • 1Department of Haematology, Hospital Clinico Universitario, Salamanca, Spain.

British Journal of Cancer
|January 1, 1989
PubMed
Summary

This study identified key prognostic factors for multiple myeloma survival, developing a new staging system. The model, using performance status and creatinine levels, effectively categorized patients into distinct risk groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Blood cancer journal·2024
Same author

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.

Leukemia supplements·2016
Same author

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.

Leukemia·2015
Same author

Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations.

Leukemia·2014
Same author

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

Leukemia·2013

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Prognostic factor analysis is crucial for developing effective staging systems in hematological malignancies.
  • Multiple myeloma (MM) staging systems aim to predict patient survival and guide treatment strategies.

Purpose of the Study:

  • To identify significant prognostic factors for survival in multiple myeloma patients.
  • To develop and validate a novel staging system for multiple myeloma using identified prognostic factors.

Main Methods:

  • Univariate analysis of 220 multiple myeloma patients to identify prognostic factors.
  • Cox regression proportional hazards model and factor analysis of principal components were employed.
  • A new regression equation was derived incorporating creatinine levels, hemoglobin, performance status, and paraprotein index.

Related Experiment Videos

Main Results:

  • Nine prognostic factors significantly impacted survival, including poor performance status, renal impairment, and anemia.
  • Performance status and creatinine levels emerged as the best combination for predicting survival via Cox regression.
  • The developed staging system categorized patients into three risk groups (A, B, C) with distinct median survival times (41, 24, and 12 months).
  • The new model demonstrated superior discriminant value compared to existing staging systems like Durie and Salmon, Merlin et al., and Carbone et al.

Conclusions:

  • Performance status, renal function, hemoglobin, and paraprotein index are critical prognostic indicators in multiple myeloma.
  • The newly developed staging system offers improved risk stratification for multiple myeloma patients.
  • This model provides a valuable tool for clinical decision-making and patient management in multiple myeloma.